These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17289895)

  • 21. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
    Dediu M; Horvat T; Tarlea A; Anghel R; Cordos I; Miron G; Iorga P; Alexandru A; Nistor C; Grozavu C; Savu C
    Lung Cancer; 2005 Jan; 47(1):93-101. PubMed ID: 15603859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
    Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
    Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
    Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
    Jaklitsch MT; Herndon JE; DeCamp MM; Richards WG; Kumar P; Krasna MJ; Green MR; Sugarbaker DJ
    J Surg Oncol; 2006 Dec; 94(7):599-606. PubMed ID: 17039491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer?
    Kris MG
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):1-4. PubMed ID: 9704668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
    Chen YM; Perng RP; Shih JF; Whang-Peng J
    Lung Cancer; 2008 Aug; 61(2):214-9. PubMed ID: 18243407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
    J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer.
    Zhang Z; Xu F; Wang S; Li N; Wang C
    Lung Cancer; 2008 Jun; 60(3):434-40. PubMed ID: 18036699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current status of adjuvant chemotherapy for resected non-small cell lung cancer.
    Socinski MA
    Semin Oncol; 1999 Oct; 26(5 Suppl 15):27-33. PubMed ID: 10566608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
    Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of adjuvant chemotherapy for non-small cell lung cancer.
    Gurubhagavatula S; Lynch TJ
    Semin Respir Crit Care Med; 2005 Jun; 26(3):298-303. PubMed ID: 16052431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC; Santoni-Rugiu E; Sørensen JB
    Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
    Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
    Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
    Pisters KM; Evans WK; Azzoli CG; Kris MG; Smith CA; Desch CE; Somerfield MR; Brouwers MC; Darling G; Ellis PM; Gaspar LE; Pass HI; Spigel DR; Strawn JR; Ung YC; Shepherd FA; ;
    J Clin Oncol; 2007 Dec; 25(34):5506-18. PubMed ID: 17954710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy.
    Chen Y; Guo W; Lu Y; Zou B
    Radiother Oncol; 2008 Sep; 88(3):351-8. PubMed ID: 18722684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
    Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
    J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.